Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Sickle cell disease (SCD) is one of the most common haemoglobinopathies worldwide, with up to 70% of global SCD annual births occuring in sub-Saharan Africa. Reports have shown that 50 to 80% of affected children in these countries die annually. Efforts geared towards understanding and the control of HbF production in SCD patients could lead to strategies for effective control of globin gene expression and therapeutic approaches that could be beneficial to individuals with haemoglobinopathies. Hemopoietic stem cells ( HSCs) are characterized by a specific miRNA signature in every state of differentiation. The role for miRNAs has become evident both in the maintenance of the "stemness" and in the early induction of differentiation by modulation of the expression of the master pluripotency genes, and during early organogenesis. miRNAs are extra regulatory mechanism in hematopoietic stem cells (HSCs) via influencing transcription profiles together with transcript stability . miRNAs have been reported to have been used to reprogram primary somatic cells toward pluripotency. Their involvement in cell editing holds potential for therapy for many genetic diseases. In this review we provide a snapshot of miRNA involvement in cell fate decisions, haemoglobin induction pathway , and their journey as some emerge prime targets for therapy in beta haemoglobinopathies.Copyright© Bentham Science Publishers; For any queries, please email at


Chinwe Okeke, Ufele Silas, Obiageli Nnodu, Odoh Clementina. HSC and MIRNA regulation with implication for foetal haemoglobin induction in beta haemoglobinopathies. Current stem cell research & therapy. 2022 Feb 21

PMID: 35189805

View Full Text